New data boosts case for extended use of AstraZeneca heart drug
AstraZeneca’s blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data. The findings, to be presented at the Aug. 26-30 European Society of Cardiology congress, are from a sub-analysis of the Pegasus clinical trial, which first reported positive results in 2015. The trial studied subjects who had a heart attack within the past one to three years and was designed to prove the value of extended use of Brilinta, which is a key product for AstraZeneca.
Source:: https://finance.yahoo.com/news/data-boosts-case-extended-astrazeneca-060120390.html
